. 2022 Nov 15;112(2):312–322. doi: 10.1007/s00392-022-02122-y

Table 2.

Absolute change of clinical characteristics over time stratified into tertiles according to QRS width progression/month. P for trend calculated by Spearman Rho

	Overall	1st Tertile	2nd Tertile	3rd Tertile	p value	Rho	p value for trend¹
ECG
PQ (ms)	1 (15)	1 (13)	1 (15)	1 (18)	0.88	0.00	0.97
Heartrate (/min)	− 1 (9)	− 1 (9)	1 (9)	− 3 (9)	0.02	− 0.12	0.06
Echocardiography
IVSd (mm)	4.00 (1.05)	3.89 (1.06)	3.92 (1.04)	4.18 (1.04)	0.1	0.14	0.05
Ejection fraction (%)	0.29 (3.92)	0.19 (4.75)	0.25 (3.61)	0.43 (3.38)	0.92	0.01	0.91
RVSP (mmHg)	1 (13)	4 (14)	1 (11)	− 2 (15)	0.46	− 0.12	0.25
LVEDD (mm)	− 0.4 (4.1)	− 1.4 (3.9)	0.0 (4.1)	0.2 (4.0)	0.06	0.14	0.03
LVESD (mm)	− 1 (9)	− 1 (6)	0 (7)	0 (12)	0.37	0.11	0.17
Medication
Betablocker (%Dose)	0 (14)	1 (14)	0 (16)	0 (12)	0.95	0.02	0.76
Mineralreceptor antagonist (%dose)	0 (15)	3 (12)	− 1 (19)	0 (13)	0.26	− 0.06	0.34
Entresto (%dose)	2 (17)	3 (15)	4 (18)	0 (16)	0.26	− 0.09	0.18
ACE inhibitor/AT2 receptor Antagonist (% Dose)	0 (14)	1 (13)	− 1 (19)	1 (9)	0.64	0.02	0.73
Dose Eq furosemid (mg)	1.9 (15.2)	0.3 (7.7)	2.8 (19.9)	2.5 (15.3)	0.51	0.07	0.28
Laboratory parameters
Haemoglobine (mmol/L)	30 (18)	29 (18)	30 (17)	32 (19)	0.46	0.07	0.26
Sodium (mmol/L)	0.6 (9.9)	2.3 (16.1)	− 0.1 (2.7)	− 0.3 (4.5)	0.33	− 0.10	0.15
Potassium (mmol/L)	0.03 (0.66)	0.13 (0.70)	0.04 (0.76)	− 0.07 (0.49)	0.07	− 0.15	0.02
NTproBNP (pg/ml)	− 44 (1,410)	21 (516)	143 (1,902)	− 297 (1,435)	0.23	− 0.07	0.29
Uric acid (µmol/L)	0.02 (1.75)	0.12 (1.31)	− 0.11 (2.38)	0.06 (1.42)	0.87	0.00	0.97
eGFR (ml/min/1.73m²)	− 1 (12)	1 (11)	1 (12)	− 3 (13)	0.08	− 0.15	0.03
Creatinine (mg/dl)	0.05 (0.30)	0.00 (0.28)	0.03 (0.20)	0.13 (0.38)	0.08	0.15	0.02
HbA1c (%)	0.09 (1.77)	0.41 (2.15)	− 0.53 (1.70)	0.25 (1.32)	0.48	− 0.03	0.79

Bold values indicate a p-value of at least < 0.05

¹Spearman rho